PRospective Multiple Myeloma Impact Study (PROMMIS)

Overview

We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to study whether this test can help your doctor to determine what treatment will be best for your multiple myeloma.

SparkCures ID 920
Enrollment 250 Patients
Trial Sponsors
  • SkylineDx
NCT Identifier

NCT02911571

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

  • Patient is at least 18 years old
  • Patients with Multiple Myeloma according to IMWG criteria or patients highly suspected of having Multiple Myeloma
  • No more than 8 weeks of first line therapy for Multiple Myeloma

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers